Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 18, 2024 (filed on Mar 18, 2024)Insider Name:Frost Phillip Md Et AlOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:500,000Price:$0.87
-
Mar 14, 2024 (filed on Mar 14, 2024)Insider Name:Frost Phillip Md Et AlOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:500,000Price:$0.89
-
Mar 13, 2024 (filed on Mar 13, 2024)Insider Name:Frost Phillip Md Et AlOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:500,000Price:$0.93
-
Mar 12, 2024 (filed on Mar 12, 2024)Insider Name:Frost Phillip Md Et AlOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:600,000Price:$0.93
-
Feb 28, 2024 (filed on Feb 28, 2024)Insider Name:Frost Phillip Md Et AlOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:500,000Price:$0.99
-
Feb 21, 2024 (filed on Feb 21, 2024)Insider Name:Frost Phillip Md Et AlOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:1,000,000Price:$0.99
-
Feb 07, 2024 (filed on Feb 07, 2024)Insider Name:Frost Phillip Md Et AlOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:1,500,000Price:$0.98
-
Jan 29, 2024 (filed on Jan 29, 2024)Insider Name:Krasno Richard MOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:30,000Price:$0.99
-
Jan 19, 2024 (filed on Jan 19, 2024)Insider Name:Frost Phillip Md Et AlOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:500,000Price:$0.98
-
Jan 18, 2024 (filed on Jan 18, 2024)Insider Name:Frost Phillip Md Et AlOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:400,000Price:$0.97
Filings by filing date
-
Mar 18, 2024 (filed on Mar 18, 2024)Insider Name:Frost Phillip Md Et AlOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:500,000Price:$0.87
-
Mar 14, 2024 (filed on Mar 14, 2024)Insider Name:Frost Phillip Md Et AlOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:500,000Price:$0.89
-
Mar 13, 2024 (filed on Mar 13, 2024)Insider Name:Frost Phillip Md Et AlOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:500,000Price:$0.93
-
Mar 12, 2024 (filed on Mar 12, 2024)Insider Name:Frost Phillip Md Et AlOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:600,000Price:$0.93
-
Feb 28, 2024 (filed on Feb 28, 2024)Insider Name:Frost Phillip Md Et AlOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:500,000Price:$0.99
-
Feb 21, 2024 (filed on Feb 21, 2024)Insider Name:Frost Phillip Md Et AlOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:1,000,000Price:$0.99
-
Feb 07, 2024 (filed on Feb 07, 2024)Insider Name:Frost Phillip Md Et AlOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:1,500,000Price:$0.98
-
Jan 29, 2024 (filed on Jan 29, 2024)Insider Name:Krasno Richard MOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:30,000Price:$0.99
-
Jan 19, 2024 (filed on Jan 19, 2024)Insider Name:Frost Phillip Md Et AlOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:500,000Price:$0.98
-
Jan 18, 2024 (filed on Jan 18, 2024)Insider Name:Frost Phillip Md Et AlOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:400,000Price:$0.97
News
Biz Brief
Sector: Healthcare | Industry: Healthcare Facilities & Services |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 4400 Biscayne Blvd. MIAMI FL 33137 |
Tel: | 1-310-6917100 |
Website: | https://www.opko.com |
IR: | See website |
Key People | ||
Phillip Frost Chairman of the Board, Chief Executive Officer | Elias A. Zerhouni President, Vice Chairman of the Board | Jane H. Hsiao Vice Chairman of the Board, Chief Technical Officer |
Adam E. Logal Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer | Charles W. Bishop Chief Executive Officer of OPKO Renal | Tony F. Cruz Chief Executive Officer, Transition Therapeutics, Inc |
Steven D. Rubin Executive Vice President - Administration, Director | Gary J. Nabel Chief Innovation Officer, Director |
Business Overview |
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd. |
Financial Overview |
For the fiscal year ended 31 December 2023, OPKO Health Inc revenues decreased 14% to $863.5M. Net loss decreased 42% to $188.9M. Revenues reflect Diagnostics segment decrease of 32% to $515.3M, United States segment decrease of 24% to $597.8M. Lower net loss reflects Pharmaceutical segment income totaling $41.2M vs. loss of $13M, Diagnostics segment loss decrease of 10% to $155.6M. |
Employees: | 3,930 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,021M as of Dec 31, 2023 |
Annual revenue (TTM): | $863.49M as of Dec 31, 2023 |
EBITDA (TTM): | -$51.69M as of Dec 31, 2023 |
Net annual income (TTM): | -$188.86M as of Dec 31, 2023 |
Free cash flow (TTM): | -$44.47M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $163.55M as of Dec 31, 2023 |
Shares outstanding: | 696,991,677 as of Feb 13, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |